BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Viroblock SA Reports Positive Results of Preclinical Studies in Antiviral Nasal Spray


3/31/2009 9:04:25 AM

GENEVA, Switzerland, March 31 /PRNewswire/ -- Viroblock SA has announced today that the first generation of VCCD Tech antiviral nasal spray formulation is active against human influenza. Viroblock's patented Cholesterol Catalytic Depletion Technology (VCCD Tech) inactivates enveloped viruses during the extra-cellular phase, by altering and destabilizing cholesterol-rich viral envelopes.

The two pre-clinical studies exposed ferrets to Influenza A Wisconsin/67/2005 and influenza A Panama/2007/99 strains, and were conducted by Retroscreen Virology Ltd, a recognized leader in the research and testing of antiviral compounds and vaccines. Both the direct inoculation and the natural transmission protocols have confirmed the effectiveness and the value of the antiviral nasal spray.

These in-vivo campaigns confirm all in laboratory in-vitro studies to date and demonstrate that VCCD Tech represents a breakthrough for inactivating a number of enveloped viruses and their strains.

"Our depletion technology shows no toxicity at the dosage we tested thus far and allegedly limits the development of any viral resistance, and makes it effective on all families of enveloped viruses, such as human and avian influenzas, SARS, AIDS, Ebola and smallpox viruses."

"This is an exciting development period for Viroblock and the most recent pre-clinical performance is a testament to our innovative and cutting-edge technology, the quality of our team, board of directors and investors."

"We, at Viroblock, leverage all our technological assets for rapidly developing the next generation of antiviral nasal sprays; I am also confident that our technology will become an important element of pandemic influenza preparedness efforts".

"Our ability to deliver tailored antiviral formulations, which can exist as colloidal suspensions, gels, creams, and aerosol sprays, opens promising business opportunities and a bright future for Viroblock.", comments CEO Thierry Pelet.

About Viroblock SA

Viroblock SA is a Swiss start-up founded in 2005, which has become a pioneer and world leader in the blocking virus transmission technology.

Its patented VCCD technology allegedly inactivates all families and strains of enveloped viruses, like human and avian influenzas, RSV, SARS, AIDS, Ebola and smallpox viruses, and leverages a mechanism of action that limits the development of any viral resistance and toxicity. VCCD Tech products exist as colloidal suspensions, gels, creams, and aerosol sprays, having specific mechanical, physical and chemical properties

The W.A. De Vigier Foundation nominated Viroblock SA as one of the 10 best technology projects of the year 2006, and the Swiss Tech Tour 2007 Selection Committee has rated Viroblock SA as part of the top 50 technology companies in Switzerland.

Viroblock was founded by Dr. Donald F. H. Wallach who was a worldwide expert in artificial and bio-membranes, and non-phospholipid vesicles.

CONTACT: Contact: Thierry Pelet, Chief Executive Officer, Viroblock SA,
Phone: +41-22-884-83-44, E-Mail: t.pelet@viroblock.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES